Telix Pharmaceuticals |
High $11.49 |
Low $11.20 |
Trades 4,718 |
Turnover $7,499,551 |
Volume 664,557 |
| 30 June 2023 at 4:12pm | ||||
|
Market Cap (15-Nov) $4,655,044,608 (204th) |
Close (30-Jun) $11.22 |
Volume (30-Jun) 664,557 |
Shortsold (9-Nov) 35,408,995 (10.40%) (16th) |
|
52w High $18.22 |
52w Low $8.26 |
P/E 178.57 |
EPS 0.15 |
[ARTICLE] Telix boss says Australia ‘horrible’ at getting drugs to patients
A news article has been posted about Telix Pharmaceuticals on the AFR. The article was published around , on 28 October 2024 at 2:26am.
Gift 5 articles to anyone you choose each month when you subscribe. Christian Behrenbruch, the co-founder and chief executive of $7 billion cancer diagnostic giant Telix Pharmaceuticals, has lashed out at Australia’s ability to make next-generation drugs ...
Read ArticleTLX was $11.22 at the close of trade on 30 June 2023
| Recent Articles about ASX:TLX | |
|---|---|
| 6-Nov | glennon - AFR
company-announcements.afr.com |
| 14-Sep | FDA Approves Telix's Brain Cancer Imaging Drug Pixclara - AFR
company-announcements.afr.com |
| 13-Sep | Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with ...
company-announcements.afr.com |
| 13-Sep | Telix Appoints David Gill as Chair - ASX Announcement - Market Index
company-announcements.afr.com |
| 21-Jul | Notice of change of interests of substantial holder - AFR
company-announcements.afr.com |
| 21-Jul | Q2 Business Update - Telix Pharmaceuticals Limited
company-announcements.afr.com |
| 19-Jul | Appendix 3H - Notification of cessation of securities - AFR
company-announcements.afr.com |
| 17-Jul | Appendix 3G - Notification of issue, conversion or payment up ... - AFR
company-announcements.afr.com |
| 4-Jul | Q1 2026 Strong Revenue Growth and Tx Pipeline Advancement
company-announcements.afr.com |
| 3-Jul | 604 Page 1 of 6 - Market Index
company-announcements.afr.com |
| Tracked |
Find all articles about Telix Pharmaceuticals, including others on the AFR, on the media page.
If you were already registered, log in here.